Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer

Abstract Background Stereotactic body radiation therapy (SBRT) has been widely used for pancreatic cancer. However, there is still a lack of studies comparing the latest SBRT techniques in terms of clinical efficacy and safety. Objectives: This study aims to evaluate three latest SBRT delivery platf...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongchun Song, Xiuli Chen, Xuyao Yu, Yang Dong, Jia Tian, Xin Wang, Yuwen Wang, Bo Jiang
Format: Article
Language:English
Published: BMC 2024-11-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-024-02080-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846172213353381888
author Yongchun Song
Xiuli Chen
Xuyao Yu
Yang Dong
Jia Tian
Xin Wang
Yuwen Wang
Bo Jiang
author_facet Yongchun Song
Xiuli Chen
Xuyao Yu
Yang Dong
Jia Tian
Xin Wang
Yuwen Wang
Bo Jiang
author_sort Yongchun Song
collection DOAJ
description Abstract Background Stereotactic body radiation therapy (SBRT) has been widely used for pancreatic cancer. However, there is still a lack of studies comparing the latest SBRT techniques in terms of clinical efficacy and safety. Objectives: This study aims to evaluate three latest SBRT delivery platforms: CyberKnife (CK), Tomography Radixact (TOMO), and Halcyon volume rotation intensity modulation therapy (VMAT) for the treatment of pancreatic cancer. Methods Sixteen patients with pancreatic cancer treated with CK were retrospectively analyzed. SBRT plans were designed using Precision and Eclipse software. CK plans were optimized in two forms: fixed collimator (CK-Fixed) and multi-leaf grating collimator (CK-MLC). TOMO plans were designed with 2.5 cm Fixed Jaw, pitch 0.123–0.43 and 4.0 modulation factors in precision system. In Eclipse 15.6 system, photon optimizer (OP) algorithm was used to design the coplanar two-arc Halcyon VMAT. The median radiation dose was 40 Gy (35–45 Gy) in 5 fractions. The effectiveness of clinical treatment was evaluated by comparing the homogeneity index (HI), conformity index (CI), coverage of the planning target volume (PTV) and dose distribution parameters of organs at risk (OAR). Results All plans met the limits of clinical target dose and OAR. CK-MLC plans had the lowest maximum dose of 2 cm normal tissue from PTV margin (D2cm), indicating a low risk of peripheral radiation damage. Additionally, the CK-MLC plans had the lowest dose parameters and provided the best protection for the kidney, spinal cord, small intestine, and duodenum, with a paired t-test p < 0.05, indicating a statistical difference. Conclusion High conformity and adjustability of CK-MLC allowed for precise complex target localization and conformal dose distribution, benefiting tumor treatment while maximally reducing damage to OAR. This study provides valuable dosimetric evidence for SBRT technique selection for pancreatic cancer.
format Article
id doaj-art-f22511c897064631926d4e51b2d9be4c
institution Kabale University
issn 2047-783X
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj-art-f22511c897064631926d4e51b2d9be4c2024-11-10T12:14:05ZengBMCEuropean Journal of Medical Research2047-783X2024-11-012911710.1186/s40001-024-02080-3Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancerYongchun Song0Xiuli Chen1Xuyao Yu2Yang Dong3Jia Tian4Xin Wang5Yuwen Wang6Bo Jiang7Department of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Radiotherapy, Tianjin HospitalDepartment of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerDepartment of Radiotherapy, Tianjin Cancer Hospital Airport HospitalDepartment of Radiotherapy, Tianjin Cancer Hospital Airport HospitalAbstract Background Stereotactic body radiation therapy (SBRT) has been widely used for pancreatic cancer. However, there is still a lack of studies comparing the latest SBRT techniques in terms of clinical efficacy and safety. Objectives: This study aims to evaluate three latest SBRT delivery platforms: CyberKnife (CK), Tomography Radixact (TOMO), and Halcyon volume rotation intensity modulation therapy (VMAT) for the treatment of pancreatic cancer. Methods Sixteen patients with pancreatic cancer treated with CK were retrospectively analyzed. SBRT plans were designed using Precision and Eclipse software. CK plans were optimized in two forms: fixed collimator (CK-Fixed) and multi-leaf grating collimator (CK-MLC). TOMO plans were designed with 2.5 cm Fixed Jaw, pitch 0.123–0.43 and 4.0 modulation factors in precision system. In Eclipse 15.6 system, photon optimizer (OP) algorithm was used to design the coplanar two-arc Halcyon VMAT. The median radiation dose was 40 Gy (35–45 Gy) in 5 fractions. The effectiveness of clinical treatment was evaluated by comparing the homogeneity index (HI), conformity index (CI), coverage of the planning target volume (PTV) and dose distribution parameters of organs at risk (OAR). Results All plans met the limits of clinical target dose and OAR. CK-MLC plans had the lowest maximum dose of 2 cm normal tissue from PTV margin (D2cm), indicating a low risk of peripheral radiation damage. Additionally, the CK-MLC plans had the lowest dose parameters and provided the best protection for the kidney, spinal cord, small intestine, and duodenum, with a paired t-test p < 0.05, indicating a statistical difference. Conclusion High conformity and adjustability of CK-MLC allowed for precise complex target localization and conformal dose distribution, benefiting tumor treatment while maximally reducing damage to OAR. This study provides valuable dosimetric evidence for SBRT technique selection for pancreatic cancer.https://doi.org/10.1186/s40001-024-02080-3Pancreatic cancerSBRTCyberknifeTOMOHalcyon VMAT
spellingShingle Yongchun Song
Xiuli Chen
Xuyao Yu
Yang Dong
Jia Tian
Xin Wang
Yuwen Wang
Bo Jiang
Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
European Journal of Medical Research
Pancreatic cancer
SBRT
Cyberknife
TOMO
Halcyon VMAT
title Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
title_full Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
title_fullStr Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
title_full_unstemmed Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
title_short Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
title_sort dosimetric comparison of multiple sbrt delivery platforms for pancreatic cancer
topic Pancreatic cancer
SBRT
Cyberknife
TOMO
Halcyon VMAT
url https://doi.org/10.1186/s40001-024-02080-3
work_keys_str_mv AT yongchunsong dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT xiulichen dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT xuyaoyu dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT yangdong dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT jiatian dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT xinwang dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT yuwenwang dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer
AT bojiang dosimetriccomparisonofmultiplesbrtdeliveryplatformsforpancreaticcancer